New hope for Early-Relapse colorectal cancer: immune booster added to chemo

This study is for people with colorectal cancer that came back within a year after finishing initial chemotherapy. It tests whether adding an immunotherapy drug called serplulimab to standard second-line chemo and targeted therapy can help control the cancer longer. About 40 participants will be randomly assigned to receive either the new combination or standard treatment alone. The goal is to see if the immune-boosting approach improves outcomes in this hard-to-treat group.